← Back to Clinical Trials
Recruiting NCT07153263

NCT07153263 Local Anaesthetic Spread and Sensory Block Range of the Retro-superior Costotransverse Ligament Space Block

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07153263
Status Recruiting
Phase
Sponsor Nanjing First Hospital, Nanjing Medical University
Condition Pulmonary Nodules
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-09-12
Primary Completion 2026-09-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Ultrasound-guided retro-SCTLBUltrasound-guided TPVB

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-09-12 with a primary completion date of 2026-09-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this clinical trial is to investigate the effects of local anesthetic diffusion range and sensory block range during retro-SCTLB(retro superior costotransverse ligament space block) and TPVB(thoracic paravertebral block) in patients undergoing CT-guided lung nodule localization. The main issue of the study is to determine the differences in the diffusion range and sensory block range of local anesthetics between the retro-SCTLB and TPVB nerve block methods.

Eligibility Criteria

Inclusion Criteria: Patients scheduled for CT-guided lung nodule localization under local anesthesia will be selected 1. aged 18-80 years 2. BMI 18-30 kg/m² 3. ASA classification I-III Exclusion Criteria: 1. Allergy to the study drug or local anesthetic; 2. History of opioid abuse; 3. Pre-existing skin infection at the puncture site of ITPN or TPVB; 4. Peripheral infectious neuropathy; 5. Dysfunction of blood coagulation

Contact & Investigator

Central Contact

Tao Shan

✉ shantao2021@163.com

📞 +8618852095135

Principal Investigator

Tao Shan

STUDY CHAIR

Nanjing First Hospital, Nanjing Medical University

Frequently Asked Questions

Who can join the NCT07153263 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Pulmonary Nodules. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07153263 currently recruiting?

Yes, NCT07153263 is actively recruiting participants. Contact the research team at shantao2021@163.com for enrollment information.

Where is the NCT07153263 trial being conducted?

This trial is being conducted at Nanjing, China, Nanjing, China.

Who is sponsoring the NCT07153263 clinical trial?

NCT07153263 is sponsored by Nanjing First Hospital, Nanjing Medical University. The principal investigator is Tao Shan at Nanjing First Hospital, Nanjing Medical University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology